Pfizer Wyeth Wsj Essay examples

754 Words Mar 6th, 2015 4 Pages
Corporate News: Pfizer Wins Prevnar 13 Approval, In Quick Boost From Wyeth Deal
Rockoff, Jonathan D. Wall Street Journal, Eastern edition [New York, N.Y] 25 Feb 2010: B.4. Turn on hit highlighting for speaking browsers by selecting the Enter button Hide highlighting

Abstract (summary)
Translate AbstractTranslate Press the Escape key to closeTranslate [[missing key: loadingAnimation]] The Food and Drug Administration approved Prevnar 13 for prevention of "pneumococcal" illnesses, such as ear infections, sepsis and meningitis, in infants and young children.

Full Text

Translate Full textTranslate Press the Escape key to closeTranslate [[missing key: loadingAnimation]] Turn on search term navigationTurn on search term navigation A
…show more content…
"That would represent a significant expansion of the population" of users, said Mark Swindell, Pfizer's president of vaccines.


Health insurers must decide whether to reimburse for the pricier vaccine, but they usually follow CDC recommendations. Credit Suisse analyst Catherine Arnold projects that Prevnar 13 will have $5.9 billion in sales in 2015, more than any other single Pfizer product. "We think it is the most important value driver for the future of Pfizer," she said. Lipitor has been Pfizer's top-selling drug, accounting for about a fifth of the company's revenue last year with $11.4 billion in sales. The Wyeth deal has generally drawn praise for boosting Pfizer's product mix, particularly the addition of vaccines like Prev nar as well as consumer and animal-health items. Pfizer has also used the takeover to cut an additional $4 billion in costs and to reorganize the company into business units, which Chief Executive Jeffrey Kindler says will help drive future growth. Mr. Kindler expressed confidence in a recent interview that the company's cost cutting and research and development would also pay dividends. "We have a very exciting late-stage pipeline," he said. Concerns remain about the company's long-term prospects, and Prevnar 13 isn't expected to provide a complete fix for the loss of Pfizer's blockbuster revenue stream. And analysts question how the combined company will be able to grow at its large size, let

Related Documents